Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples